OXO Translational Science

Oxolife is a clinical-stage biotechnology company based in Barcelona, Spain, specializing in the development of innovative treatments for female infertility. The company's primary focus is on improving embryo implantation, a critical phase in the reproductive process that is often the cause of assisted reproduction failure. Its lead candidate, OXO-001, is a first-in-class oral small molecule that enhances endometrial receptivity, making the uterus more welcoming to the embryo. Unlike traditional fertility drugs that target ovulation or egg quality, OXO-001 acts directly on the uterine lining. Recent Phase 2 clinical data from the OXO-ART trial has demonstrated that OXO-001 significantly increases pregnancy and live birth rates in women undergoing embryo transfer. Oxolife aims to integrate this therapy into standard assisted reproduction protocols to improve outcomes for patients globally. The company is also exploring the potential of its lead molecule in other conditions such as polycystic ovary syndrome and endometriosis.